Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer

被引:31
作者
Luo, Xin [1 ]
Xu, Jing [1 ]
Yu, Jianhua [2 ,3 ]
Yi, Ping [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 3, Dept Obstet & Gynecol, Chongqing, Peoples R China
[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Los Angeles, CA 90068 USA
[3] City Hope Natl Med Ctr, Hematol Malignancies Res Inst, Los Angeles, CA 90068 USA
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
ovarian cancer; tumor microenvironment; immune; genetic; epigenetic; cytokine; NATURAL-KILLER-CELLS; MONOCLONAL-ANTIBODY; T-CELLS; ANTITUMOR-ACTIVITY; MALIGNANT ASCITES; NONCODING RNAS; PHASE-I; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MACROPHAGES;
D O I
10.3389/fimmu.2021.692360
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Reciprocal signaling between immune cells and ovarian cancer cells in the tumor microenvironment can alter immune responses and regulate disease progression. These signaling events are regulated by multiple factors, including genetic and epigenetic alterations in both the ovarian cancer cells and immune cells, as well as cytokine pathways. Multiple immune cell types are recruited to the ovarian cancer tumor microenvironment, and new insights about the complexity of their interactions have emerged in recent years. The growing understanding of immune cell function in the ovarian cancer tumor microenvironment has important implications for biomarker discovery and therapeutic development. This review aims to describe the factors that shape the phenotypes of immune cells in the tumor microenvironment of ovarian cancer and how these changes impact disease progression and therapy.
引用
收藏
页数:16
相关论文
共 160 条
  • [1] MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer
    An, Yuanyuan
    Yang, Qing
    [J]. LIFE SCIENCES, 2020, 242
  • [2] Non-coding RNA networks in cancer
    Anastasiadou, Eleni
    Jacob, Leni S.
    Slack, Frank J.
    [J]. NATURE REVIEWS CANCER, 2018, 18 (01) : 5 - 18
  • [3] A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Angevin, Eric
    Tabernero, Josep
    Elez, Elena
    Cohen, Steven J.
    Bahleda, Rastilav
    van Laethem, Jean-Luc
    Ottensmeier, Christian
    Lopez-Martin, Jose A.
    Clive, Sally
    Joly, Florence
    Ray-Coquard, Isabelle
    Dirix, Luc
    Machiels, Jean-Pascal
    Steven, Neil
    Reddy, Manjula
    Hall, Brett
    Puchalski, Thomas A.
    Bandekar, Rajesh
    de Velde, Helgi van
    Tromp, Brenda
    Vermeulen, Jessica
    Kurzrock, Razelle
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2192 - 2204
  • [4] STAT1-associated intratumoural T(H)1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer
    Au, Katrina K.
    Le Page, Cecile
    Ren, Runhan
    Meunier, Liliane
    Clement, Isabelle
    Tyrishkin, Kathrin
    Peterson, Nichole
    Kendall-Dupont, Jennifer
    Childs, Timothy
    Francis, Julie-Ann
    Graham, Charles H.
    Craig, Andrew W.
    Squire, Jeremy A.
    Mes-Masson, Anne-Marie
    Koti, Madhuri
    [J]. JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2016, 2 (04) : 259 - 270
  • [5] The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
    Baci, Denisa
    Bosi, Annalisa
    Gallazzi, Matteo
    Rizzi, Manuela
    Noonan, Douglas M.
    Poggi, Alessandro
    Bruno, Antonino
    Mortara, Lorenzo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [6] Dendritic cell subsets and locations
    Balan, Sreekumar
    Saxena, Mansi
    Bhardwaj, Nina
    [J]. IMMUNOBIOLOGY OF DENDRITIC CELLS, PT A, 2019, 348 : 1 - 68
  • [7] JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
    Banerjee, Shubhasree
    Biehl, Ann
    Gadina, Massimo
    Hasni, Sarfaraz
    Schwartz, Daniella M.
    [J]. DRUGS, 2017, 77 (05) : 521 - 546
  • [8] Nanotechnology in ovarian cancer: Diagnosis and treatment
    Barani, Mahmood
    Bilal, Muhammad
    Sabir, Fakhara
    Rahdar, Abbas
    Kyzas, George Z.
    [J]. LIFE SCIENCES, 2021, 266
  • [9] Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference
    Bast, Robert C., Jr.
    Matulonis, Ursula A.
    Sood, Anil K.
    Ahmed, Ahmed A.
    Amobi, Adaobi E.
    Balkwill, Frances R.
    Wielgos-Bonvallet, Monicka
    Bowtell, David D. L.
    Brenton, James D.
    Brugge, Joan S.
    Coleman, Robert L.
    Draetta, Giulio F.
    Doberstein, Kai
    Drapkin, Ronny I.
    Eckert, Mark A.
    Edwards, Robert P.
    Elias, Kevin M.
    Ennis, Darren
    Futreal, Andrew
    Gershenson, David M.
    Greenberg, Roger A.
    Huntsman, David G.
    Ji, Jennifer Xiao Ye
    Kohn, Elise C.
    Iavarone, Claudia
    Lengyel, Ernst R.
    Levine, Douglas A.
    Lord, Christopher J.
    Lu, Zhen
    Mills, Gordon B.
    Modugno, Francesmary
    Nelson, Brad H.
    Odunsi, Kunle
    Pilsworth, Jessica A.
    Rottapel, Robert K.
    Powell, Daniel J., Jr.
    Shen, Li
    Shih, Ie-Ming
    Spriggs, David R.
    Walton, Josephine
    Zhang, Kaiyang
    Zhang, Rugang
    Zou, Lee
    [J]. CANCER, 2019, 125 (12) : 1963 - 1972
  • [10] NON-CODING RNAs IN DEVELOPMENT AND DISEASE: BACKGROUND, MECHANISMS, AND THERAPEUTIC APPROACHES
    Beermann, Julia
    Piccoli, Maria-Teresa
    Viereck, Janika
    Thum, Thomas
    [J]. PHYSIOLOGICAL REVIEWS, 2016, 96 (04) : 1297 - 1325